Most therapeutic tests of osteoarthritis treatments are assessed by criteria based either on fundamental data or on clinical data, which is often subjective.
used to determine the spatiotemporal indices (stride length and duration), ldnematic indices (walkng speed, velocity peak), and symmetry criteria that are relevant to the assessment of locomotor handicaps in patients with osteoarthritis.
This study examined the progression of locomotor abilities in 11 subjects aged 49-69 (mean 60.9) years with knee osteoarthritis before and after treatment with a non-steroidal anti-inflammatory drug. Naproxen sodium (1100 mg) was given once a day for seven days. The condition before and after treatment was evaluated by quantitative analysis of locomotion, estimation of pain on a visual analogue scale, and assessment of the degree of functional disability.
Significant improvement in locomotor indices (proportional increase in walking speed 17-8%) and in degree of pain (proportional decrease 27%) as estimated on the analogue scale was found after non-steroidal anti-inflammatory drug treatment.
The lack of a significant correlation between the decrease in pain experienced by the patients and the objective improvement of their functional capabilities emphasises the need in further studies of new treatments to accompany the patients' own assessments of self improvement with a quantitative analysis of the way in which they walk. , and height 150-174 cm (mean 162-3) were included in the study. All had knee osteoarthritisasdiagnosedby clinical observation and radiography (joint space narrowing, alterations of subchondral bone-that is, sclerosis, microgeodes, and osteophytes). Duration of their osteoarthritis ranged from one to 15 years (mean 6-1 years). Five patients had osteoarthritis of the right knee, four of the left knee, and two of both knees. The osteoarthritis was painful and handicapping. All patients had difficulty in normal walking on flat ground. One patient had recurring inflammationarticular effusion, inflammatory pain at specific times. Seven patients had been successfully treated with anti-inflammatory drugs before the trial, but all antalgic or anti-inflammatory treatments had been stopped for at least three days before the study.
ETHICS
The study was approved by the Timone Hospital ethics committee, and all patients gave their informed consent to participation in the trial. in the temporal location of velocity peaks during the swing phase. In fast walking the following differences were noted after one week's treatment: an increase in walking speed (p<0-01), in stride length (p<002), and a decrease in stride duration (p<0-05). The stance duration (p<005) and absolute double support phase duration (p<005) decreased, but the decrease in the relative double support phase duration (with respect to total cycle duration) was not significant. No significant difference was observed in the temporal location of the velocity peaks.
Regularity of walk Regularity of walk was analysed by studying the standard deviations of stride length in normal and fast walking. No significant difference was found.
Symmetry of walk
The symmetry criteria chosen were the differences between the right and left legs for step length, velocity peak location, and support phase duration. Data underlying velocity variations made voluntarily, and those underlying variations due to a treatment which reduces the mechanical constraints to which the patient is subject.
In summary, naproxen sodium treatment had an undeniably positive effect on the amount of pain experienced (mean decrease of pain 27%) and the functional abilities of the patients studied (mean increase of waLking speed 17T8%). These two types of improvement were not correlated, however-that is, the increased walking speed was not linked to the decrease in pain. This finding stresses the value of simultaneously analysing the effects of a new therapeutic treatment on both pain and functional abilities in order to judge its effectiveness. 
